We have an excellent product in our range for the support of the haematopoietic system — Revilab SL 07. It contains peptides of the B-link of the immune system, bone marrow and vascular wall.
Subscribe to mailing and get the latest news and discounts of our store.>
Vasoprotective properties of peptides IN VIVO
Our last scientific lecture explored the topic of vasoprotective properties of peptides in vitro. Today we will review these properties in vivo.
As you may know, peptides are able to protect blood vessels from damage and improve blood microcirculation. They activate the synthesis of nitric oxide, which dilates blood vessels and improves blood flow.
Studies have shown that peptides can be effective in prevention and treatment of various diseases of the cardiovascular system, including hypertension, ischemic heart disease, myocardial infarction and stroke.
Our new lecture examines the vasoprotective properties of peptides, such as Ventfort and Vesugen (KED) that can be used to treat cardiovascular disease in the elderly. These peptides possess a wide spectrum of action and contribute to improved blood circulation, memory normalization and intellectual abilities.
The scientific lecture is prepared by Ekaterina Mironova, Ph.D.:
- a senior research fellow of the laboratory for Molecular Mechanisms of Ageing from the Department of biogerontology of Saint-Petersburg Institute of bioregulation and gerontology
- a senior research fellow of the Molecular Biomedicine Center - Saint-Petersburg State Research Institute of Phthisiopulmonology of the Ministry of Healthcare of the Russian Federation
Thus, the study of vasoprotective properties of peptides in vivo is a perspective area for the development of new methods of treatment and prevention of cardiovascular diseases.
We wish you a pleasant reading experience, we hope you find the lecture useful, informative and substantial!
View the text of the lecture — Vasoprotective properties of peptides IN VIVO
Vasoprotective properties of peptides IN VIVO
Ekaterina S. Mironova, Ph.D.
Cardiovascular disease (CVD) is one of the most common pathology with a high mortality risk in elderly and senile people. The main causes of death are ischemic heart disease and atherosclerosis. According to statistics from the World Health Organization, myocardial infarction is the cause of death in more than 30% of cases. In Russia, CVD accounts for approximately 55% of the causes of total mortality. To date, there is a trend towards a decrease in the average age of CVD manifestation. A feature of the course of CVD in the elderly is a combination of various body systems pathology, which leads to the use of various pharmaceuticals.
Existing medicines used in the treatment of CVD in people of older age groups have limitations due to side effects: they can cause dysfunction of the gastrointestinal tract, increased synthesis of liver enzymes, clouding of the lens, disorders in the hematopoietic system, mental disorders, myopathy.
In this regard, the search for new effective and safe treatments for CVD is particularly relevant. The study of the functional activity of blood vessels under normal conditions and in pathology, as well as the possibility of regulating these processes with the peptides, opens up new prospects for the development of vasoprotective drugs that are highly effective at treating CVD and free of side effects [Khavinson V.H., 2020].
From the polypeptide complex Ventfort®, which was isolated from the vessels of young animals, the tripeptide Vesugen® (KED, Lys-Glu-Asp) was synthesized. It was found that this tripeptide has a wide spectrum of action in various experimental models.
Studies were conducted on the effectiveness of using Ventfort® to stimulate the respiratory and cardiovascular systems functions in a model of experimental hypothermia in rats. After applying Ventfort®, the heart rate during the cooling process was statistically significantly higher, and the respiratory rate began to decrease later than in the control. The temperature limit for breathing cessation after the use of Ventfort® decreased, the time to breathing cessation increased by 2 times compared to the control. Thus, Ventfort® slows down the cold depression process of respiration and cardiac activity [Arokina N.K., 2022].
The effect of Ventfort® on the cerebral cortex microcirculation in spontaneously hypertensive rats of different ages (6 and 12 months) was also studied. It has been shown that a single course of Ventfort® administration to young animals increases the density of the microvascular network in the pial membrane (the system of veins and arteries of the pia mater) by 1.2 times. In hypertensive rats at the age of 12 months, after two courses of the Ventfort® administration, the density of the microvascular network increased by 1.6 times; the level of perfusion (blood flow intensity) increased by 15% relative to intact animals of the same age. Animals in this group were more easily tolerated to cerebral vasospasm (application of a vasoconstrictor to the surface of the brain): they maintained a high level of tissue oxygen saturation with unchanged perfusion rates [Sokolova I.B, 2017, 2017]. In old rats aged 22–24 months, the density of the pial microvascular network increased significantly (approximately 2.5–2.8 times); The constrictor (contractile) and dilator (expansion) reactions of pial arterioles increased when norepinephrine or acetylcholine was applied to the surface of the brain, respectively. At the same time, perfusion in the the cerebral cortex tissue did not increase, but the degree of blood saturation in this tissue area microvessels was [Sokolova I.B, 2016].
Intravenous Vesugen® administration resulted in a significant dose-dependent decrease in blood pressure and blood flow in the abdominal aorta, carotid artery and cardiac output in cats. In experiments using the Vesugen® administration in animals, a pronounced increase in the calculated indicators of total peripheral vascular resistance and vascular resistance of the carotid artery and abdominal aorta regions was also noted. It can be assumed that the increase in the calculated indicators of vascular resistances in response to the Vesugen® administration could be a consequence of cardiac output and blood flow decreasing in these arteries.
In addition, Vesugen® had a normalizing effect on the capillary condition in a mild periodontitis model in rats. The Vesugen® increased their resistance and permeability, and also improved the microvasculature condition of the gingival and periodontal mucosa.
Ventfort® and Vesugen® highly effects on the animals vascular system in various experimental models of vascular pathology. It was demonstrated the homeostatic, endothelial protective and vasoprotective effects of this peptides.
This opens up new prospects for the medicines development that are highly effective at treating CVD and free of side effects.
We are excited to introduce you brand new complex geroprotectors of a new type based on peptide extracts - GPL® Man and GPL® Femme - created as long joint ventures between Peptides and Saint-Petersburg Institute of bioregulation and gerontology.
The leading task of bioregulation is activating the processes of elimination of toxins from the body. A new product “Cleantestin”, developed by the Peptides company, is the embodiment of this idea.
